 PALO ALTO, Calif., May 10, 2021 PRNewswire -- Kodiak Sciences Inc. Nasdaq: KOD, a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021. 